ArriVent BioPharma shares plunged 58% during morning trading after its lead oral cancer pill failed to meaningfully delay disease progression in a late-stage trial. The therapy, firmonertinib, was tested in untreated patients with advanced non-small-cell lung cancer. CEO Bing Yao said the data fell short of therapeutic goals.
ArriVent Shares Plunge on Trial Failure
ArriVent BioPharma shares dropped after its lung cancer drug failed to significantly delay disease progression in a late stage trial. The therapy extended median survival modestly compared to chemotherapy. The company is now evaluating the full dataset.
Xurve View
Insights:
Xurve View





